In late November 2008 it was announced that Sanguine, a company engaged in the development of synthetic red blood cells, has signed a letter of intent, which is subject to a five million dollar capitalization agreement, to acquire Rockland Technimed, an MRI imaging technology company. The managements of both the companies see the potential in merging the two technologies to meet the clinical need for real-time in vivo metabolic imaging using a natural element and a bioinert molecule compared to the only alternative current methodology using radio tracers.
